{"doi":"10.1002/adma.201805955","title":"Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia‐Activated Prodrug Tirapazamine Therapy for Metastatic Tumors","abstract":"<jats:title>Abstract</jats:title><jats:p>Hypoxia‐activated prodrugs (HAPs) have the potential to selectively kill hypoxic cells and convert tumor hypoxia from a problem to a selective treatment advantage. However, HAPs are unsuccessful in most clinical trials owing to inadequate hypoxia within the treated tumors, as implied by a further substudy of a phase II clinical trial. Here, a novel strategy for the combination of HAPs plus vascular disrupting agent (VDA) nanomedicine for efficacious solid tumor therapy is developed. An effective VDA nanomedicine of poly(<jats:sc>l</jats:sc>‐glutamic acid)‐<jats:italic>graft</jats:italic>‐methoxy poly(ethylene glycol)/combretastatin A4 (CA4‐NPs) is prepared and can selectively enhance tumor hypoxia and boost a typical HAP tirapazamine (TPZ) therapy against metastatic 4T1 breast tumors. After treatment with the combination of TPZ plus CA4‐NPs, complete tumor reduction is observed in 4T1 xenograft mice (initial tumor volume is 180 mm<jats:sup>3</jats:sup>), and significant tumor shrinkage and antimetastatic effects are observed in challenging large tumors with initial volume of 500 mm<jats:sup>3</jats:sup>. The report here highlights the potential of using a combination of HAPs plus VDA nanomedicine in solid tumor therapy.</jats:p>","journal":"Advanced Materials","year":2019,"id":654417,"datarank":0.8062917611526249,"base_score":5.375278407684165,"endowment":5.375278407684165,"self_citation_contribution":0.8062917611526249,"citation_network_contribution":0.0,"self_endowment_contribution":0.8062917611526249,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":215,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":8,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":848319,"name":"Zhaohui Tang","orcid":"0000-0003-4726-4305","position":1,"is_corresponding":false},{"id":1707917,"name":"Chenyang Hu","orcid":null,"position":2,"is_corresponding":false},{"id":506712,"name":"Dawei Zhang","orcid":"0000-0002-0841-7826","position":3,"is_corresponding":false},{"id":993182,"name":"Na Shen","orcid":"0000-0003-4362-9207","position":4,"is_corresponding":false},{"id":810585,"name":"Haiyang Yu","orcid":"0000-0003-3460-6716","position":5,"is_corresponding":false},{"id":249857,"name":"Xuesi Chen","orcid":"0000-0003-3542-9256","position":6,"is_corresponding":false},{"id":1707916,"name":"Shengcai Yang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia‐Activated Prodrug Tirapazamine Therapy for Metastatic Tumors","abstract":"<jats:title>Abstract</jats:title><jats:p>Hypoxia‐activated prodrugs (HAPs) have the potential to selectively kill hypoxic cells and convert tumor hypoxia from a problem to a selective treatment advantage. However, HAPs are unsuccessful in most clinical trials owing to inadequate hypoxia within the treated tumors, as implied by a further substudy of a phase II clinical trial. Here, a novel strategy for the combination of HAPs plus vascular disrupting agent (VDA) nanomedicine for efficacious solid tumor therapy is developed. An effective VDA nanomedicine of poly(<jats:sc>l</jats:sc>‐glutamic acid)‐<jats:italic>graft</jats:italic>‐methoxy poly(ethylene glycol)/combretastatin A4 (CA4‐NPs) is prepared and can selectively enhance tumor hypoxia and boost a typical HAP tirapazamine (TPZ) therapy against metastatic 4T1 breast tumors. After treatment with the combination of TPZ plus CA4‐NPs, complete tumor reduction is observed in 4T1 xenograft mice (initial tumor volume is 180 mm<jats:sup>3</jats:sup>), and significant tumor shrinkage and antimetastatic effects are observed in challenging large tumors with initial volume of 500 mm<jats:sup>3</jats:sup>. The report here highlights the potential of using a combination of HAPs plus VDA nanomedicine in solid tumor therapy.</jats:p>","is_dataset_classified":null,"base_score":5.375278407684165,"endowment":5.375278407684165,"datacite_reuse_total":8,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30680816","pmcid":null,"openalex_id":"https://openalex.org/W2914293180","authors":[],"funders":[{"funder_name":"Ministry of Science and Technology of the People's Republic of China","grant_id":"2016YFC1100701","title":null},{"funder_name":"Ministry of Science and Technology of the People's Republic of China","grant_id":"2018ZX09711003‐012","title":null},{"funder_name":"Ministry of Science and Technology of China","grant_id":"2018ZX09711003-012","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"51673189","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"51833010","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"51873206","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"51520105004","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"51673185","title":null}],"total_grants":8,"fwci":11.0462,"citation_percentile":0.9928701,"influential_citations":0,"citation_trend":[{"year":2019,"count":21},{"year":2020,"count":33},{"year":2021,"count":40},{"year":2022,"count":40},{"year":2023,"count":26},{"year":2024,"count":31},{"year":2025,"count":21},{"year":2026,"count":3}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fadma.201805955","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/adma.201805955","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/adma.201805955","host_type":"publisher"},{"url":"https://advanced.onlinelibrary.wiley.com/doi/pdf/10.1002/adma.201805955","host_type":"publisher"},{"url":"https://doi.org/10.1002/adma.201805955","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/30680816","host_type":"repository"}],"fields_of_study":["Nanoplatforms for cancer theranostics","RNA Interference and Gene Delivery","Cancer, Hypoxia, and Metabolism","Animals","Breast Neoplasms","Cell Line, Tumor","Drug Synergism","Mice","Mice, Inbred BALB C","Nanomedicine","Neoplasm Metastasis","Prodrugs","Stilbenes","Tirapazamine","Tumor Hypoxia","Xenograft Model Antitumor Assays"],"mesh_terms":["Tumor Hypoxia","Tirapazamine","Animals","Breast Neoplasms","Drug Synergism","Mice, Inbred BALB C","Neoplasm Metastasis","Prodrugs","Stilbenes","Xenograft Model Antitumor Assays","Cell Line, Tumor","Nanomedicine","Mice"],"keywords":["Tirapazamine","Prodrug","Hypoxia (environmental)","Nanomedicine","Materials science","Tumor hypoxia","Pharmacology","Cancer research","Combretastatin","Radiation therapy","Nanotechnology","Medicine","Organic chemistry","Chemistry","Internal medicine","Cytotoxicity","Nanoparticle","Biochemistry","In vitro","Oxygen","Biology","Microtubule","Hypoxia","Vascular Disrupting Agent","Metastatic Breast Carcinoma","Hypoxia-activated Prodrug"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.14131082.v1","title":"Additional file 1 of Ginsenoside Rg3 inhibits pulmonary fibrosis by preventing HIF-1α nuclear localisation","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.14131082","title":"Additional file 1 of Ginsenoside Rg3 inhibits pulmonary fibrosis by preventing HIF-1α nuclear localisation","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19588758.v1","title":"Additional file 1 of Double-activation of mitochondrial permeability transition pore opening via calcium overload and reactive oxygen species for cancer therapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19588758","title":"Additional file 1 of Double-activation of mitochondrial permeability transition pore opening via calcium overload and reactive oxygen species for cancer therapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26082652.v1","title":"Additional file 1 of Sonodynamic and sonomechanical effect on cellular stemness and extracellular physicochemical environment to potentiate chemotherapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26082652","title":"Additional file 1 of Sonodynamic and sonomechanical effect on cellular stemness and extracellular physicochemical environment to potentiate chemotherapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26612402.v1","title":"Additional file 1 of A multi-functional hypoxia/esterase dual stimulus responsive and hyaluronic acid-based nanomicelle for targeting delivery of chloroethylnitrosouea","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26612402","title":"Additional file 1 of A multi-functional hypoxia/esterase dual stimulus responsive and hyaluronic acid-based nanomicelle for targeting delivery of chloroethylnitrosouea","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T06:31:25.443851Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}